We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.

中文翻译：

---

CD33剪接位点的基因型与接受抗CD33药物偶联物SGN-CD33A的患者的预后无关。

我们测试了影响CD33剪接的单核苷酸多态性（SNP）是否预测了接受新型CD33抗体-药物偶联物SGN-CD33A的成人急性髓细胞性白血病（AML）的治疗反应。CD33剪接位点SNP rs12459419的这种基因型与临床反应（两组中30％的CR / CRi），无事件生存期或总生存期无关。